We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$318M
AUM Growth
+$98.7M
Cap. Flow
+$13.5M
Cap. Flow %
4.23%
Top 10 Hldgs %
67.71%
Holding
36
New
11
Increased
7
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$19.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.1M
3
CYTK icon
Cytokinetics
CYTK
+$13.9M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$9.48M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.55M

Top Sells

Rank Stock Value
1
ATRA icon
Atara Biotherapeutics
ATRA
+$25.3M
2
EPZM
Epizyme, Inc
EPZM
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$8.12M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$2.58M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 77.71%
2 Miscellaneous 22.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTX
26
Akari Therapeutics
AKTX
$20.8M
$1.46M 0.46%
126
– –
GILD icon
27
CALL
Gilead Sciences
GILD
$181B
$1.19M 0.38%
11,800
+8,545
+263% +$889K
NRX
28
DELISTED
NEPHROGENEX INC COM
NRX
$941K 0.3%
+588,235
New +$1.37M
QLTI
29
DELISTED
QLT Inc
QLTI
$266K 0.08%
100,000
-538,900
-84% -$1.52M
LRMR icon
30
CALL
Larimar Therapeutics
LRMR
$417M
$63K 0.02%
+833
New +$134K
ATRA icon
31
Atara Biotherapeutics
ATRA
$92.3M
– –
-32,138
Closed -$25.3M
GYRE icon
32
Gyre Therapeutics
GYRE
$699M
– –
-498
Closed -$261K
RGLS
33
CALL
DELISTED
Regulus Therapeutics
RGLS
– –
-11
Closed -$35K
CASC
34
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-157,250
Closed -$2.58M
OREX
35
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-93,796
Closed -$1.98M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2015 Portfolio in Review

As of Q4 2015, EcoR1 Capital held 36 positions worth $318M, up 45% from $220M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $13.5M of net new capital in Q4 2015, opening 11 new positions and adding to 7 existing holdings. Its largest new stake was Kura Oncology: 2,450,000 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 88% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Epizyme, Inc, an estimated $11.8M trimmed.

  • EcoR1 Capital's largest Q4 2015 buy was Kura Oncology: 2,450,000 shares worth $20.6M.
  • EcoR1 Capital added most to Five Prime Therapeutics, Inc. in Q4 2015, an estimated $19.1M increase.
  • EcoR1 Capital's biggest Q4 2015 reduction was Epizyme, Inc, cutting an estimated $11.8M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q4 2015, selling an estimated $25.3M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $318M portfolio in Q4 2015.
  • EcoR1 Capital opened 11 new positions and closed 5 in Q4 2015.
  • EcoR1 Capital's portfolio value rose 45% quarter-over-quarter to $318M.

Based on EcoR1 Capital's 13F filing for Q4 2015, filed 16 Feb 2016.